

# Loss-of-function mutations in *SLC30A8* protect against type 2 diabetes

Jason Flannick<sup>1-3</sup>, Gudmar Thorleifsson<sup>4</sup>, Nicola L Beer<sup>1,5</sup>, Suzanne B R Jacobs<sup>1</sup>, Niels Grarup<sup>6</sup>, Noël P Burt<sup>1</sup>, Anubha Mahajan<sup>7</sup>, Christian Fuchsberger<sup>8</sup>, Gil Atzmon<sup>9,10</sup>, Rafn Benediktsson<sup>11</sup>, John Blangero<sup>12</sup>, Don W Bowden<sup>13-16</sup>, Ivan Brandslund<sup>17,18</sup>, Julia Brosnan<sup>19</sup>, Frank Burslem<sup>20</sup>, John Chambers<sup>21-23</sup>, Yoon Shin Cho<sup>24</sup>, Cramer Christensen<sup>25</sup>, Desirée A Douglas<sup>26</sup>, Ravindranath Duggirala<sup>12</sup>, Zachary Dymek<sup>1</sup>, Yossi Farjoun<sup>1</sup>, Timothy Fennell<sup>1</sup>, Pierre Fontanillas<sup>1</sup>, Tom Forsén<sup>27,28</sup>, Stacey Gabriel<sup>1</sup>, Benjamin Glaser<sup>29,30</sup>, Daniel F Gudbjartsson<sup>4</sup>, Craig Hanis<sup>31</sup>, Torben Hansen<sup>6,32</sup>, Astradur B Hreidarsson<sup>11</sup>, Kristian Hveem<sup>33</sup>, Erik Ingelsson<sup>7,34</sup>, Bo Isomaa<sup>35,36</sup>, Stefan Johansson<sup>37-39</sup>, Torben Jørgensen<sup>40-42</sup>, Marit Eika Jørgensen<sup>43</sup>, Sekar Kathiresan<sup>1,44-46</sup>, Augustine Kong<sup>4</sup>, Jaspal Kooner<sup>22,23,47</sup>, Jasmina Kravic<sup>48</sup>, Markku Laakso<sup>49</sup>, Jong-Young Lee<sup>50</sup>, Lars Lind<sup>51</sup>, Cecilia M Lindgren<sup>1,7</sup>, Allan Linneberg<sup>40,41,52</sup>, Gisli Masson<sup>4</sup>, Thomas Meitinger<sup>53</sup>, Karen L Mohlke<sup>54</sup>, Anders Molven<sup>37,55,56</sup>, Andrew P Morris<sup>7,57</sup>, Shobha Potluri<sup>58</sup>, Rainer Rauramaa<sup>59,60</sup>, Rasmus Ribel-Madsen<sup>6</sup>, Ann-Marie Richard<sup>19</sup>, Tim Rolph<sup>19</sup>, Veikko Salomaa<sup>61</sup>, Ayellet V Segrè<sup>1,2</sup>, Hanna Skärstrand<sup>26</sup>, Valgerdur Steinthorsdottir<sup>4</sup>, Heather M Stringham<sup>8</sup>, Patrick Sulem<sup>4</sup>, E Shyong Tai<sup>62-64</sup>, Yik Ying Teo<sup>62,65-68</sup>, Tanya Teslovich<sup>8</sup>, Unnur Thorsteinsdottir<sup>4,69</sup>, Jeff K Trimmer<sup>19</sup>, Tiinamaija Tuomi<sup>27,35</sup>, Jaakko Tuomilehto<sup>70-72</sup>, Fariba Vaziri-Sani<sup>26</sup>, Benjamin F Voight<sup>1,73,74</sup>, James G Wilson<sup>75</sup>, Michael Boehnke<sup>8</sup>, Mark I McCarthy<sup>5,7,76</sup>, Pål R Njølstad<sup>1,37,77</sup>, Oluf Pedersen<sup>6</sup>, Go-T2D Consortium<sup>78</sup>, T2D-GENES Consortium<sup>78</sup>, Leif Groop<sup>48,79</sup>, David R Cox<sup>58</sup>, Kari Stefansson<sup>4,69</sup> & David Altshuler<sup>1-3,44,45,80,81</sup>

Loss-of-function mutations protective against human disease provide *in vivo* validation of therapeutic targets<sup>1-3</sup>, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ~150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in *SLC30A8*, which encodes an islet zinc transporter (ZnT8)<sup>4</sup> and harbors a common variant (p.Trp325Arg) associated with T2D risk and glucose and proinsulin levels<sup>5-7</sup>. Collectively, carriers of protein-truncating variants had 65% reduced T2D risk ( $P = 1.7 \times 10^{-6}$ ), and non-diabetic Icelandic carriers of a frameshift variant (p.Lys34Serfs\*50) demonstrated reduced glucose levels ( $-0.17$  s.d.,  $P = 4.6 \times 10^{-4}$ ). The two most common protein-truncating variants (p.Arg138\* and p.Lys34Serfs\*50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of *SLC30A8* suggested that reduced zinc transport increases T2D risk<sup>8,9</sup>, and phenotypic heterogeneity was observed in mouse *Slc30a8* knockouts<sup>10-15</sup>. In contrast, loss-of-function mutations in humans provide strong evidence that *SLC30A8* haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention.


Genome-wide association studies (GWAS) have identified 65 genomic loci associated with T2D risk<sup>7</sup>, highlighting previously unidentified

pathological pathways. Translation of these loci into novel therapeutic targets<sup>16</sup> requires the identification of causal mutations and genes, as well as information on the directional relationship between protein activity and disease risk<sup>17</sup>. Toward this end, loss-of-function mutations that protect against disease (without adverse phenotypes) are among the most useful findings from human genetics, suggesting targets that, upon inhibition, might prevent disease in the general population.

To identify loss-of-function variants protective against T2D, in 2009, a collaboration of Pfizer, Inc., Massachusetts General Hospital, the Broad Institute and Lund University sequenced the exons of 115 genes near T2D association signals identified by GWAS (Supplementary Fig. 1 and Supplementary Tables 1 and 2) in 758 individuals from Finland or Sweden (modeling previous studies<sup>18</sup>). To increase power, we selected individuals at the extremes of T2D risk, including 352 young and lean T2D cases and 406 elderly and obese euglycemic controls<sup>19</sup> (Supplementary Table 3). In total, we identified 1,768 nonsynonymous variants (1,683 single-nucleotide variants (SNVs) and 85 indels), 1,474 (83%) with minor allele frequency (MAF) of <1% and 1,108 (63%) observed in only one individual. We found no evidence of association with T2D when testing individual variants or a burden of rare variants within genes (Supplementary Fig. 2). Genotyping of 71 select SNVs (showing nominally significant association ( $P < 0.05$ ) or predicted to affect

A full list of author affiliations appears at the end of the paper.

Received 18 September 2013; accepted 10 February 2014; published online 2 March 2014; doi:10.1038/ng.2915



**Figure 1** Overexpression of Arg138\* and Ser34fs\*50 ZnT8 in HeLa cells. We sought to experimentally evaluate whether the Arg138\* or Ser34fs\*50 ZnT8 variants resulted in decreased ZnT8 expression and/or activity. **(a)** Depiction of the C-terminally V5-tagged ZnT8 proteins encoded by *SLC30A8* ORFs (tag highlighted in green). **(b)** Protein blot of HeLa lysates after transient overexpression of V5-tagged ZnT8 variants (using antibody to the V5 tag). Antibody against tubulin was used as a loading control for each sample, and untransfected cell lysate was used to demonstrate the specificity of the antibody to V5.

**(c,d)** Immunofluorescent staining of ZnT8 variants in HeLa **(c)** and Ins1e **(d)** cells. ZnT8 was detected using antibodies against the C-terminal V5 tag or the N terminus of the endogenous protein (both green), as indicated. BFP-V5 and untransfected HeLa cells serve as controls. Cells were also stained with Hoechst 33342 to mark nuclei (blue). Within each row, identical exposure times were used for all images. **(e)** ZnT8 variant expression, as detected by immunostaining with antibody to V5, following 4-h treatment with inhibitors of the lysosome (chloroquine, 100  $\mu$ M) or proteasome (MG132, 10  $\mu$ M). Images were acquired using either a 63 $\times$  (top row) or 10 $\times$  (all other rows) objective and identical exposure times. Scale bars, 100  $\mu$ m.

protein structure) in up to 13,884 additional individuals (6,388 cases and 7,496 controls) also yielded results consistent with the null distribution of no association with T2D (**Supplementary Fig. 3**).

Among these SNVs, we noted a nonsense variant (c.412C>T, p.Arg138\*) in *SLC30A8* (transcript accession [NM\\_173851](#)) that trended toward protection from T2D rather than risk (7 case and 21 control observations, odds ratio (OR) = 0.38,  $P = 0.05$ ). To propagate this variant into larger sample sizes, we added p.Arg138\* to the design of the Illumina Human Exome array (along with six other variants from the original sequencing that were predicted to cause protein truncation). Using this array, we genotyped the 13,884 individuals already genotyped for p.Arg138\*, as well as 7,212 additional Finnish or Swedish individuals (**Supplementary Tables 4 and 5**). In the combined analysis of 10,534 cases and 10,562 controls, the protective association for p.Arg138\* remained nominally significant (OR = 0.46,  $P = 0.01$ ; **Supplementary Table 6**). We genotyped p.Arg138\* in an additional 26,566 European individuals (8,210 T2D cases and 18,356 controls; **Supplementary Table 7**), with 16 heterozygotes observed (2 cases and 14 controls). Combining all available genotype data for the variant encoding p.Arg138\*, heterozygosity was estimated to yield a 53% reduction in T2D risk ( $P = 0.0067$ ,  $N = 48,115$ ).

*SLC30A8* encodes an islet zinc transporter ZnT8 ([NP\\_776250](#); ref. 20), which is necessary for zinc flux into  $\beta$  cell insulin-secretory granules<sup>4</sup> and subsequent insulin crystallization<sup>10,12</sup>. Upon co-secretion with insulin, zinc also fulfills autocrine and paracrine signaling roles<sup>21</sup>. A previously identified common missense variant in *SLC30A8* (rs13266634; c.973T>A, p.Trp325Arg) associates with T2D risk<sup>7,22</sup> and glucose<sup>5</sup> and proinsulin<sup>6</sup> levels with significance far exceeding genome-wide thresholds ( $P < 5 \times 10^{-8}$ ).

Cellular characterization has suggested that the risk-increasing allele encoding p.Trp325Arg reduces ZnT8 zinc transport activity<sup>8,9</sup>.

In *Slc30a8* knockout mice, observations range from no effect on insulin secretion or glucose homeostasis to modest hyperglycemia on a high-fat diet, with the phenotype varying with sex and genetic background<sup>8–15</sup>. Furthermore, data obtained from a recent  $\beta$  cell-specific *Slc30a8* knockout mouse model suggest a multi-organ effect on the phenotype, with circulating zinc also influencing hepatic insulin clearance in these mice<sup>21</sup>. Thus, the directional relationship between perturbed ZnT8 function and whole-organism phenotype is uncertain, despite much genetic and biological data.

Because the observed protective association between p.Arg138\* and T2D risk was statistically modest, we sought additional evidence. Unfortunately, the near absence of the p.Arg138\* variant outside of western Finland limited our ability to further characterize its effect in other populations (**Supplementary Figs. 4 and 5**). We thus sought to identify a wider spectrum of protein-truncating variants in *SLC30A8* by investigating the catalog of 35 million variants collected by deCODE Genetics through whole-genome sequencing<sup>23</sup>. The variant encoding p.Arg138\* was not observed in this data set. However, an independent protein-truncating variant was observed at a frequency of 0.17%—a deletion (c.100\_106delAAAGATC, p.Lys34Serfs\*50; **Supplementary Figs. 6 and 7**) predicted to cause a frameshift and loss of all six transmembrane domains encoded by the islet-specific transcript ([NM\\_173851](#)) of *SLC30A8* (ref. 4).

Heterozygosity for the variant encoding p.Lys34Serfs\*50 was associated with 80% reduced T2D risk, with 2 observations of this variant in 2,953 T2D cases (0.03%) versus 248 observations in 67,919 controls (0.18%; OR = 0.18,  $P = 0.004$ ; **Supplementary Tables 8 and 9**). Taking into consideration the ancestral relationship between Norwegian and Icelandic populations, we genotyped the variant in 5,714 Norwegians (**Supplementary Table 8**) and observed no carriers in 1,645 cases and 3 carriers in 4,069 controls. Combining the evidence for the p.Lys34Serfs\*50 and p.Arg138\* variants strengthened the association

**Table 1 Association of *SLC30A8* variants with T2D**

Variant	Ancestry	Country	Cohort	N		Carriers		Allele frequency		OR (95% CI)	P
				Cases	Controls	Cases	Controls	Cases (%)	Controls (%)		
p.Arg138*	European	Finland	Botnia	3,727	5,440	9	39	0.12	0.36	0.47 (0.27–0.81)	0.0067
	European	Sweden	Malmö	6,960	5,480	2	3	0.014	0.027		
	European	Sweden	PIVUS/ULSAM	270	1,734	1	3	0.19	0.087		
	European	Denmark	Danish	3,889	7,869	0	9	0.0	0.057		
	European	Finland	Finnish	4,050	8,696	1	2	0.012	0.011		
	South Asian	Singapore	Singapore Indians	562	585	1	1	0.089	0.085		
	European	UK	UKT2D	321	319	0	1	0.0	0.16		
p.Lys34Serfs*50	European	Iceland	deCODE	2,953	67,919	2	248	0.034	0.18	0.17 (0.05–0.52)	0.0019
	European	Norway	HUNT2	1,645	4,069	0	3	0.0	0.037		
c.71+2T>A	African American	United States	WFS	501	527	1	0	0.1	0.0	0.30 (0.14–0.64)	0.0021
	African American	United States	JHS	530	533	0	1	0.0	0.094		
p.Met50Ile	European	Germany	KORA	97	91	0	1	0.0	0.55		
	c.271+G>A	East Asian	Korea	KARE	520	551	0	1	0.0		
c.419–1G>C	South Asian	Singapore	Singapore Indians	562	585	0	1	0.0	0.085		
	South Asian	UK	LOLIPOP	530	537	1	0	0.094	0.0		
p.Trp152*	European	Finland	Botnia	134	180	0	1	0.0	0.28		
p.Gln174*	South Asian	UK	LOLIPOP	530	537	1	5	0.094	0.47		
c.572+1G>A	African American	United States	JHS	530	533	0	1	0.0	0.094		
	p.Tyr284*	South Asian	UK	LOLIPOP	530	537	0	2	0.0		
p.Ile291Phefs*2	South Asian	Singapore	Singapore Indians	562	585	0	1	0.0	0.085		
	African American	United States	JHS	530	533	0	1	0.0	0.094		
p.Ser327Thrs*55	African American	United States	WFS	501	527	0	2	0.0	0.19		
Combined	–	–	–	30,433	118,701	19	326	–	–	0.34 (0.21–0.53)	1.7 × 10 <sup>–6</sup>

Through sequencing and genotyping of ~150,000 individuals across 5 ancestry groups, a spectrum of 12 rare predicted protein-truncating variants was identified in *SLC30A8*. Shown for each variant are ancestry group, cohort, number of genotyped cases and controls (N), number of cases and controls observed to carry the variant, and observed allele frequencies in cases and controls. ORs and P values were computed separately for three groups of variants: p.Arg138\*, p.Lys34Serfs\*50 and the remaining variants. For p.Arg138\* and p.Lys34Serfs\*50, for which more than ten carriers were observed, statistics were computed separately for each cohort (Online Methods and **Supplementary Note**) and then combined via a fixed-effects meta-analysis. For the remaining variants, an association score was computed by comparing the aggregate frequencies of variant carriers in cases and controls. These three statistics were combined via a random-effects meta-analysis to produce combined estimates of risk and statistical significance (bottom row). Variant counts and frequencies were computed on the basis of all studied individuals, whereas ORs and P values were computed with correction for sample structure (population stratification and genetic relatedness; **Supplementary Note**); thus, displayed ORs differ from those computed solely from frequency estimates. CI, confidence interval.

between *SLC30A8* protein-truncating variants and reduced T2D risk (combined OR = 0.32,  $P = 2.4 \times 10^{-4}$ ).

Both rare *SLC30A8* variants are bioinformatically predicted to cause ZnT8 truncation and, consequently, to affect activity. To test this prediction, we assessed overexpressed V5-tagged ZnT8 variants (Trp325, Arg325, \*138 (as well as Arg138\*) and Ser34fs\*50) in HeLa cells<sup>20</sup> (**Fig. 1a**). Despite similar RNA transcript levels for all variants (**Supplementary Fig. 8**), only Trp325 and Arg325 ZnT8 proteins were easily detectable in cells<sup>8</sup>, with Arg138\*, \*138 and Ser34fs\*50 ZnT8 present at low to undetectable levels (**Fig. 1b,c**). Similar results were obtained using antibodies against the native protein or the V5 tag in protein blot analysis (**Fig. 1b**) and immunofluorescence (**Fig. 1c**) and in HeLa as well as in Ins1 rat insulinoma cells (**Fig. 1d**). Coexpression of \*138 or Ser34fs\*50 ZnT8 with Trp325 ZnT8 did not decrease expression of the full-length allele or rescue expression of either truncating variant (**Supplementary Fig. 9**).


We hypothesized that decreased expression of these two mutants might be due to protein instability and/or enhanced degradation. After treatment of cells with chloroquine or MG132 (lysosomal and proteasomal inhibitors, respectively<sup>24</sup>), higher \*138 and Ser34fs\*50 ZnT8 expression was detected via immunofluorescence (but remained undetectable via protein blot analysis; **Fig. 1e** and **Supplementary Fig. 10**). These results are consistent with but do not prove instability and subsequent degradation of these truncated proteins<sup>25</sup>. In additional experiments (data not shown), we observed zinc transport in cells expressing Arg325 and Trp325 ZnT8 but not in cells expressing \*138 or Ser34fs\*50 ZnT8 (an expected result given the low levels of mutant protein). Further experiments are needed to assess the *in vivo* impact of these variants,

including their susceptibility to nonsense-mediated decay and potential dominant-negative effects on protein oligomerization.

These genetic and functional data suggest that *SLC30A8* haploinsufficiency reduces T2D risk. However, confidence in this conclusion would be further increased through the observation of multiple additional putative loss-of-function variants demonstrating protective effects. As part of the Genetics of Type 2 Diabetes (Go-T2D) and Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples (T2D-GENES) consortia, we sequenced *SLC30A8* exons in 12,294 individuals spanning multiple ancestry groups (**Supplementary Table 10**). Nine additional protein-truncating variants were identified—2 frameshift indels and 2 nonsense, 4 splice-site and 1 initiator codon SNV—in 23 heterozygous individuals of African-American, East Asian and South Asian ancestry (**Supplementary Data Set 1**). The variant encoding p.Arg138\* was seen in three additional carriers (one case and two controls); the variant encoding p.Lys34Serfs\*50 was not observed.

In aggregate, carriers of these additional variants exhibited 60% reduced T2D risk (4 observations of the variants in cases versus 18 observations in controls; OR = 0.38,  $P = 0.0025$ ), with similar effects and statistical significance observed upon analysis of only carriers of frameshift or nonsense variants (2 observations of variants in cases versus 13 observations in controls; OR = 0.37,  $P = 0.0027$ ). Combining all data from sequencing and genotyping in 149,134 subjects, heterozygosity for any of the 12 protein-truncating variants was associated with 65% reduced T2D risk (OR = 0.34,  $P = 1.7 \times 10^{-6}$ ), which represents a statistically significant association even after correction for the ~20,000 genes in the human genome (**Table 1**).

**Figure 2** Protein-truncating variants identified in *SLC30A8*. Through sequencing and genotyping of nearly 150,000 individuals across 5 ancestry groups, we identified 12 *SLC30A8* variants—each rare and predicted to cause premature protein truncation. **(a)** Shown is the position of each variant on the islet-specific *SLC30A8* transcript (NM\_173851; ref. 20). p.Met50Ile is predicted to alter the initiator codon in other transcripts of *SLC30A8*. Lines are drawn from each variant to the ancestry groups in which carriers were observed, with greater width corresponding to more observations. Lines are further drawn from each ancestry group to the populations (cohorts) in which carriers were identified. From left to right, the cohorts are JHS, WFS, Botnia, Danish, deCODE, Finnish, HUNT2, KORA, Malmö, PIVUS/ULSAM, WTCCC, LOLIPOP, Singapore Indians and KARE (cohort information appears in the **Supplementary Note**). Ancestry groups or cohorts with no observations are not shown. **(b)** Graphical representation of the case (red) and control (blue) frequencies for each observed variant. Wider bars correspond to more observations. A quantitative and complete representation of these data is given in **Table 1**.



We investigated potential confounding factors for the observed protective association. First, we assessed whether the haplotypic background encoding the p.Trp325Arg variant might influence results. Whereas the variants encoding p.Lys34Serfs\*50 and p.Met50Ile were observed on the protective common variant haplotype, the remaining variants (including the one encoding p.Arg138\*) were observed on the risk-associated common variant haplotype. Thus, independent protective protein-truncating variants were observed on opposite haplotypic backgrounds encoding p.Trp325Arg. Second, we tested for a survivor effect, where carriers of rare variants with diabetes would die at a younger age than non-carriers. However, (i) carrier ages did not differ significantly from non-carrier ages for either p.Arg138\* ( $69.6 \pm 8.4$  years versus  $65.5 \pm 11.0$  years for cases ( $P > 0.1$ ),  $46.4 \pm 15.7$  years versus  $50.3 \pm 15.5$  years for controls ( $P > 0.1$ )) or p.Lys34Serfs\*50 ( $70.5 \pm 4.5$  years versus  $65.6 \pm 13.8$  years for cases ( $P > 0.1$ ),  $48.5 \pm 20.1$  years versus  $50.0 \pm 23.2$  years for controls ( $P > 0.1$ )), and (ii) p.Lys34Serfs\*50 association attained equivalent significance even when the analysis was restricted to age-matched controls. Finally, although we employed well-established methods using linear mixed models or principal components to control for population structure<sup>26</sup>, we acknowledge the noted challenges to address this potential confounder in rare variant association studies<sup>27</sup>. We had insufficient data to control for stratification via a family-based transmission disequilibrium test (pedigree information was only available for Icelanders, with three carrier parents all transmitting the risk-associated allele to affected children). However, the consistent association of multiple independent protein-truncating variants across multiple cohorts and ancestry groups argues against population stratification being responsible for protective association.

These data thus provide compelling evidence that mutations inactivating one copy of *SLC30A8* reduce T2D risk in humans. In addition to T2D risk, the common *SLC30A8* variant encoding p.Trp325Arg is associated with proinsulin and fasting plasma glucose levels at genome-wide significance<sup>5,6</sup>, as well as with 2-h glucose levels after an oral glucose tolerance test (OGTT) at nominal significance (**Supplementary Table 11**)<sup>27</sup>. We asked whether rare protein-truncating

*SLC30A8* variants also affected T2D-related phenotypes, particularly glycemic traits that might be indicative of altered islet function.

Among the traits analyzed (**Supplementary Table 12**), the strongest statistical evidence for association was observed in Icelanders between p.Lys34Serfs\*50 and random (non-fasting) glucose levels: non-diabetic carriers of the protective allele had lower glucose levels ( $\beta = -0.17$  s.d.;  $N = 182$  carriers;  $P = 4.6 \times 10^{-4}$ ), with a consistent effect seen in three Norwegian carriers ( $\beta = -0.3$  s.d.;  $P > 0.1$ ). Glucose levels were lower at 1 h in the small number of p.Lys34Serfs\*50 carriers characterized by OGTT ( $\beta = -0.73$  s.d.;  $N = 4$  carriers;  $P = 0.05$ ). We did not observe a significant difference in fasting glucose or insulin levels, although the directions of effect were consistent with those described above—these levels were lower for fasting glucose (average  $\beta = -0.10$  s.d.;  $N = 146$  carriers;  $P > 0.1$ ) and higher for fasting insulin ( $\beta = 0.24$  s.d.;  $N = 52$  carriers;  $P = 0.09$ ). The parallel directionality of glucose levels and T2D risk is similar to the pattern observed for p.Trp325Arg, where the T2D-protective allele also associates with lower glucose levels (**Supplementary Table 9**), providing further evidence against a survivor effect or population stratification driving the protective association.

In summary, we identified 12 rare predicted protein-truncating *SLC30A8* variants (**Fig. 2**). Carriers of these variants had 65% reduced T2D risk at a level of significance adequate to correct for the  $\sim 20,000$  genes in the human genome ( $P = 1.7 \times 10^{-6}$ ). Non-diabetic Icelandic carriers of p.Lys34Serfs\*50 also demonstrated lower glucose levels ( $\beta = -0.17$  s.d.,  $P = 4.6 \times 10^{-4}$ ). Notably, initial sequencing of 115 genes in 758 individuals with extreme T2D phenotypes resulted in only 2 observations of the variant encoding p.Arg138\*, without significant evidence of association of low-frequency or rare variants, individually or in aggregate, for any of the sequenced genes. Rather, establishing the association of *SLC30A8* protein-truncating variants with T2D protection at levels of exome-wide significance (with correction for 20,000 genes) required genotyping of  $\sim 150,000$  individuals spanning multiple ancestry groups. Detecting similar effects in genes without previous evidence of association may require analysis on a similar or larger scale, for not only T2D but also for other complex traits.

Previous modeling of the relationship between ZnT8 activity and T2D risk centered on p.Trp325Arg, which results in mildly attenuated zinc transport that is concomitant with increased T2D risk<sup>8</sup>, and *Slc30a8* knockout mice, where phenotypic heterogeneity is observed<sup>13,15</sup>. We find a clear and consistent association between putative *SLC30A8* loss-of-function variants and T2D risk across multiple ancestry groups, demonstrating convincingly that a 50% reduction in gene dosage protects against T2D in humans. These data reject the model in which loss of ZnT8 function is associated with as little as a 1.2-fold increase in T2D risk (similar to the increase in risk observed for the common p.Trp325Arg variant) at significance of  $P \approx 1 \times 10^{-9}$ . Phenotypic interrogation of human mutation carriers is needed to determine the physiological mechanism behind this protective association and to establish the effects of *SLC30A8* haploinsufficiency in the pancreas and other tissues<sup>21</sup>.

The observed human genetics data present several implications for *SLC30A8* function in T2D pathophysiology. The identification of multiple disease-associated protein-altering variants in *SLC30A8* unambiguously (albeit unsurprisingly) documents *SLC30A8* as the causal gene behind GWAS association signals. The observation that protein-truncating variants protect against T2D defines the directional relationship between ZnT8 activity and T2D risk in humans. The expanded *SLC30A8* allelic series offers a more functionally informative catalog of variation compared to the p.Trp325Arg variant alone, enabling future experiments investigating potential mechanisms. Although substantial work is required to understand how reduced ZnT8 activity lowers T2D risk, the current observations motivate experiments to test ZnT8 inhibition in T2D treatment in human populations.

## METHODS

Methods and any associated references are available in the [online version of the paper](#).

**Accession codes.** *SLC30A8* transcript, [NM\\_173851](#) (ref. 20); ZnT8 protein, [NP\\_776250](#) (ref. 20).

*Note: Any Supplementary Information and Source Data files are available in the online version of the paper.*

## ACKNOWLEDGMENTS

This manuscript is dedicated to the memory of David R. Cox, our dear friend and colleague, who was relentlessly supportive of this work—and more generally, of the use of human genetics to improve human health. He is missed, but his legacy goes on. We gratefully acknowledge the contribution of all ~150,000 participants from the various population studies that contributed to this work. J.F. was supported in part by US National Institutes of Health (NIH) Training Grant 5-T32-GM007748-33. D.A. was supported by funding from the Doris Duke Charitable Foundation (2006087). N.L.B. was supported by a Fulbright Diabetes UK Fellowship (BDA 11/0004348). This work was supported in part by funding to the Broad Institute (principal investigator D.A.) from Pfizer, Inc. Funding for the GoT2D and T2D-GENES studies was provided by grants 5U01DK085526 (NIH/NIDDK; Multiethnic Study of Type 2 Diabetes Genes), DK088389 (NIH/NIDDK; Low-Pass Sequencing and High-Density SNP Genotyping for Type 2 Diabetes) and U54HG003067 (National Human Genome Research Institute (NHGRI); Large-Scale Sequencing and Analysis of Genomes), as well as by NIH grants U01 DK085501, U01 DK085524, U01 DK085545 and U01 DK085584. The Malmö Preventive Project and the Scania Diabetes Registry were supported by grants from the Swedish Research Council (Dnr 521-2010-3490 to L.G. and Dnr 349-2006-237 to the Lund University Diabetes Centre), as well as by a European Research Council (ERC) grant (GENETARGET T2D, GA269045) and two European Union grants (ENGAGE (2007-201413) and CEDD3 (2008-223211)) to L.G. The Botnia study was supported by funding from the Sigrid Juselius Foundation and the Folkhälsan Research Foundation. P.R.N. was funded by the ERC (AdG 293574), the Research Council of Norway (197064/V50), the KG Jebsen Foundation, the University of Bergen, the Western Norway Health Authority, the European Association for the Study of Diabetes Sabbatical Leave Programme and Innovest. The Danish studies

were supported by the Lundbeck Foundation (Lundbeck Foundation Centre for Applied Medical Genomics in Personalised Disease Prediction, Prevention and Care (LuCamp); <http://www.lucamp.org/>) and the Danish Council for Independent Research. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen, partially funded by an unrestricted donation from the Novo Nordisk Foundation (<http://www.metabol.ku.dk/>). The PIVUS/ULSAM cohort was supported by Wellcome Trust grants WT098017, WT064890 and WT090532, Uppsala University, the Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation. The METSIM study was supported by the Academy of Finland (contract 124243), the Finnish Heart Foundation, the Finnish Diabetes Foundation, Tekes (contract 1510/31/06), the Commission of the European Community (HEALTH-F2-2007-201681) and grants R01DK062370 and R01DK072193 (NIH/NIDDK) and grant Z01HG000024 (NHGRI). The FUSION study was supported by grants R01DK062370 and R01DK072193 (NIH/NIDDK) and grant Z01HG000024 (NHGRI). The DR's EXTRA Study was supported by the Ministry of Education and Culture of Finland (627; 2004-2011), the Academy of Finland (102318; 123885), Kuopio University Hospital, the Finnish Diabetes Association, the Finnish Heart Association and the Päivikki and Sakari Sohlberg Foundation and by grants from the European Commission Framework Programme 6 Integrated Project (EXGENESIS); LSHM-CT-2004-005272, City of Kuopio and Social Insurance Institution of Finland (4/26/2010). V. Salomaa is funded by the Academy of Finland, grant 139635, and by the Finnish Foundation for Cardiovascular Disease. Sequencing and genotyping of British individuals was supported by Wellcome Trust grants WT090367, WT090532 and WT098381 and by NIH/NIDDK grant U01-DK085545. Funding for the Jackson Heart Study (JHS) was provided by the National Heart, Lung, and Blood Institute (NHLBI) and by the National Institute on Minority Health and Health Disparities (N01 HC-95170, N01 HC-95171 and N01 HC-95172). A.P.M. acknowledges support from Wellcome Trust grants WT098017, WT090532 and WT064890. F.V.-S. and H.S. were supported by the European Union Seventh Framework Programme, DIAPREPP (Diabetes Type 1 Prediction, Early Pathogenesis and Prevention, grant agreement 202013), and by the Swedish Child Diabetes Foundation (Barndiabetesfonden).

## AUTHOR CONTRIBUTIONS

This manuscript describes an analysis spanning four initially distinct sequencing studies—a collaborative project between Pfizer, Massachusetts General Hospital, the Broad Institute and Lund University entitled “Towards Therapeutic Targets for Type 2 Diabetes and Myocardial Infarction in the Background of Type 2 Diabetes” (PMBL), an effort by deCODE Genetics to use whole-genome sequencing and imputation to identify and genotype over 35 million variants in up to 370,000 Icelanders<sup>23</sup>, the Genetics of Type 2 Diabetes (GoT2D) project and the Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples (T2D-GENES) project—as well as four additional genotyping efforts. The overall study bringing together data from these efforts was coordinated by J.F. and D.A., with final analysis combining data from all variants collected by J.F. The manuscript was written by J.F., D.A. and K.S., and all authors reviewed, edited and approved the manuscript. Author contributions specific to the sequencing or genotyping studies are as follows.

**Pfizer, Massachusetts General Hospital, Broad Institute and Lund University.** *Study design.* B.F.V., F.B., S.P., N.P.B., D.R.C., T.R., L.G., S.K. and D.A. *Clinical investigation and sample management.* T. Forsén, B.I., T. Tuomi, L.G. and J. Kravic. *Sequencing, genotyping and data processing.* N.P.B., T. Fennell and S.G.; performed at the Broad Institute. *Analysis.* J.F. (p.Arg138\*) and A.V.S. (p.Trp325Arg). *Functional studies.* N.L.B., S.B.R.J., Z.D. (cellular models), F.V.-S., H.S. and D.A.D. (screen for carrier autoantibodies). *Leadership and management.* N.P.B., A.-M.R., J. Brosnan, J.K.T., S.K., T.R., L.G., D.R.C. and D.A.

**deCODE Genetics.** *Clinical investigation and sample management.* A.B.H. and R.B. *Sequencing, genotyping and data processing.* G.T., V. Steinthorsdottir, P.S., G.M., D.F.G. and A.K.; performed at deCODE Genetics. *Analysis.* G.T., V. Steinthorsdottir, P.S., G.M., D.F.G. and A.K. *Leadership and management.* A.K., U.T. and K.S.

**T2D-GENES and Go-T2D.** *Clinical investigation and sample management.* G.A., J. Blanger, D.W.B., J.C., Y.S.C., R.D., B.G., C.H., J. Kooner, M.L., T.M., J.-Y.L., E.S.T., Y.Y.T. and J.G.W. *Sequencing and data processing.* N.P.B., Y.F., T. Fennell and S.G.; performed at the Broad Institute. *Analysis.* J.F. (*SLC30A8*), P.F., A.P.M. and T. Teslovich (exome wide). *Leadership and management.* M.I.M., M.B. and D.A. HUNT2 sample management, genotyping, analysis and leadership involved K.H., A. Molven, S.J. and P.R.N. Danish sample management, genotyping, analysis and leadership involved N.G., R.R.-M., M.E.J., C.C., I.B., A.L., T.J., T.H. and O.P. PIVUS/ULSAM sample management, genotyping, analysis and leadership involved A. Mahajan, C.M.L., L.L., E.I. and A.P.M. Finnish sample management, genotyping,

analysis and leadership involved C.F., H.M.S., M.L., K.L.M., R.R., V. Salomaa, J.T. and M.B.

#### COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the [online version of the paper](#).

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Nassar, M.A. *et al.* Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. *Proc. Natl. Acad. Sci. USA* **101**, 12706–12711 (2004).
- Cohen, J. *et al.* Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in *PCSK9*. *Nat. Genet.* **37**, 161–165 (2005).
- Sullivan, D. *et al.* Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. *J. Am. Med. Assoc.* **308**, 2497–2506 (2012).
- Chimienti, F. *et al.* *In vivo* expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. *J. Cell Sci.* **119**, 4199–4206 (2006).
- Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105–116 (2010).
- Strawbridge, R.J. *et al.* Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes* **60**, 2624–2634 (2011).
- Morris, A.P. *et al.* Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat. Genet.* **44**, 981–990 (2012).
- Nicolson, T.J. *et al.* Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. *Diabetes* **58**, 2070–2083 (2009).
- Rutter, G.A. Think zinc: new roles for zinc in the control of insulin secretion. *Islets* **2**, 49–50 (2010).
- Lemaire, K. *et al.* Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. *Proc. Natl. Acad. Sci. USA* **106**, 14872–14877 (2009).
- Pound, L.D. *et al.* Deletion of the mouse *Slc30a8* gene encoding zinc transporter-8 results in impaired insulin secretion. *Biochem. J.* **421**, 371–376 (2009).
- Wijesekara, N. *et al.* Beta cell-specific *Znt8* deletion in mice causes marked defects in insulin processing, crystallisation and secretion. *Diabetologia* **53**, 1656–1668 (2010).
- Pound, L.D. *et al.* The physiological effects of deleting the mouse *Slc30a8* gene encoding zinc transporter-8 are influenced by gender and genetic background. *PLoS ONE* **7**, e40972 (2012).
- Hardy, A.B. *et al.* Effects of high-fat diet feeding on *Znt8*-null mice: differences between  $\beta$ -cell and global knockout of *Znt8*. *Am. J. Physiol. Endocrinol. Metab.* **302**, E1084–E1096 (2012).
- da Silva Xavier, G., Bellomo, E.A., McGinty, J.A., French, P.M. & Rutter, G.A. Animal models of GWAS-identified type 2 diabetes genes. *J. Diabetes Res.* **2013**, 906590 (2013).
- van de Bunt, M. & Gloyn, A.L. From genetic association to molecular mechanism. *Curr. Diab. Rep.* **10**, 452–466 (2010).
- Plenge, R.M., Scolnick, E.M. & Altshuler, D. Validating therapeutic targets through human genetics. *Nat. Rev. Drug Discov.* **12**, 581–594 (2013).
- Nejentsev, S., Walker, N., Riches, D., Egholm, M. & Todd, J.A. Rare variants of *IFIH1*, a gene implicated in antiviral responses, protect against type 1 diabetes. *Science* **324**, 387–389 (2009).
- Guey, L.T. *et al.* Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare variants. *Genet. Epidemiol.* doi:10.1002/gepi.20572 (9 February 2011).
- Chimienti, F., Devergnas, S., Favier, A. & Seve, M. Identification and cloning of a  $\beta$ -cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. *Diabetes* **53**, 2330–2337 (2004).
- Tamaki, M. *et al.* The diabetes-susceptible gene *SLC30A8/ZnT8* regulates hepatic insulin clearance. *J. Clin. Invest.* **123**, 4513–4524 (2013).
- Sladek, R. *et al.* A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* **445**, 881–885 (2007).
- Gudmundsson, J. *et al.* A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. *Nat. Genet.* **44**, 1326–1329 (2012).
- Bloom, J. & Pagano, M. Experimental tests to definitively determine ubiquitylation of a substrate. *Methods Enzymol.* **399**, 249–266 (2005).
- Waters, P.J. Degradation of mutant proteins, underlying “loss of function” phenotypes, plays a major role in genetic disease. *Curr. Issues Mol. Biol.* **3**, 57–65 (2001).
- Mathieson, I. & McVean, G. Differential confounding of rare and common variants in spatially structured populations. *Nat. Genet.* **44**, 243–246 (2012).
- Price, A.L., Zaitlen, N.A., Reich, D. & Patterson, N. New approaches to population stratification in genome-wide association studies. *Nat. Rev. Genet.* **11**, 459–463 (2010).
- Saxena, R. *et al.* Genetic variation in *GIPR* influences the glucose and insulin responses to an oral glucose challenge. *Nat. Genet.* **42**, 142–148 (2010).

<sup>1</sup>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. <sup>2</sup>Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. <sup>3</sup>Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. <sup>4</sup>deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. <sup>5</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. <sup>6</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. <sup>7</sup>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. <sup>8</sup>Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA. <sup>9</sup>Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. <sup>10</sup>Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, USA. <sup>11</sup>Department of Endocrinology and Metabolism, Landspítali University Hospital, Reykjavik, Iceland. <sup>12</sup>Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, USA. <sup>13</sup>Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. <sup>14</sup>Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. <sup>15</sup>Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. <sup>16</sup>Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. <sup>17</sup>Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark. <sup>18</sup>Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark. <sup>19</sup>Cardiovascular & Metabolic Diseases Research Unit, Pfizer, Inc., Cambridge, Massachusetts, USA. <sup>20</sup>Cardiovascular and Metabolic Diseases Practice, Prescient Life Sciences, London, UK. <sup>21</sup>Department of Epidemiology and Biostatistics, Imperial College London, London, UK. <sup>22</sup>Imperial College Healthcare National Health Service (NHS) Trust, London, UK. <sup>23</sup>Ealing Hospital NHS Trust, Middlesex, UK. <sup>24</sup>Department of Biomedical Science, Hallym University, Chuncheon, Korea. <sup>25</sup>Department of Internal Medicine and Endocrinology, Vejle Hospital, Vejle, Denmark. <sup>26</sup>Unit of Diabetes and Celiac Diseases, Department of Clinical Sciences, Lund University, Malmö, Sweden. <sup>27</sup>Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. <sup>28</sup>Diabetes Care Unit, Vaasa Health Care Centre, Vaasa, Finland. <sup>29</sup>Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. <sup>30</sup>Israel Diabetes Research Group (IDRG), Holon, Israel. <sup>31</sup>Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, USA. <sup>32</sup>Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. <sup>33</sup>Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Levanger, Norway. <sup>34</sup>Molecular Epidemiology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. <sup>35</sup>Folkhalsan Research Centre, Helsinki, Finland. <sup>36</sup>Department of Social Services and Health Care, Jakobstad, Finland. <sup>37</sup>KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway. <sup>38</sup>Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway. <sup>39</sup>Department of Biomedicine, University of Bergen, Bergen, Norway. <sup>40</sup>Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark. <sup>41</sup>Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. <sup>42</sup>Faculty of Medicine, University of Aalborg, Aalborg, Denmark. <sup>43</sup>Steno Diabetes Center, Gentofte, Denmark. <sup>44</sup>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. <sup>45</sup>Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA. <sup>46</sup>Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. <sup>47</sup>National Heart and Lung Institute (NHLI), Imperial College London, Hammersmith Hospital, London, UK. <sup>48</sup>Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden. <sup>49</sup>Department of Medicine, University of Eastern Finland, Kuopio Campus and Kuopio University Hospital, Kuopio, Finland. <sup>50</sup>Center for Genome Science, Korea National Institute of Health, Osong Health Technology, Chungcheongbuk-do, Korea. <sup>51</sup>Department of Medical Sciences, Uppsala University, Uppsala, Sweden. <sup>52</sup>Department of Clinical Experimental Research, Glostrup University Hospital, Glostrup, Denmark. <sup>53</sup>Institute of Human Genetics, Technical University Munich, Munich, Germany. <sup>54</sup>Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA. <sup>55</sup>Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway. <sup>56</sup>Department of Pathology, Haukeland University Hospital, Bergen, Norway. <sup>57</sup>Department of Biostatistics, University of Liverpool, Liverpool, UK. <sup>58</sup>Applied Quantitative Genotherapeutics, Pfizer, Inc., South San Francisco, California, USA. <sup>59</sup>Kuopio Research Institute of Exercise Medicine, Kuopio, Finland. <sup>60</sup>Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital,

Kuopio, Finland. <sup>61</sup>National Institute for Health and Welfare (THL), Helsinki, Finland. <sup>62</sup>Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore. <sup>63</sup>Department of Medicine, National University of Singapore, National University Health System, Singapore. <sup>64</sup>Duke–National University of Singapore Graduate Medical School, Singapore. <sup>65</sup>Centre for Molecular Epidemiology, National University of Singapore, Singapore. <sup>66</sup>Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore. <sup>67</sup>Graduate School for Integrative Science and Engineering, National University of Singapore, Singapore. <sup>68</sup>Department of Statistics and Applied Probability, National University of Singapore, Singapore. <sup>69</sup>Faculty of Medicine, University of Iceland, Reykjavík, Iceland. <sup>70</sup>Centre for Vascular Prevention, Danube-University Krems, Krems, Austria. <sup>71</sup>Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland. <sup>72</sup>Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia. <sup>73</sup>Department of Pharmacology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. <sup>74</sup>Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. <sup>75</sup>Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA. <sup>76</sup>Oxford National Institute for Health Research (NIHR) Biomedical Research Centre, Churchill Hospital, Oxford, UK. <sup>77</sup>Department of Pediatrics, Haukeland University Hospital, Bergen, Norway. <sup>78</sup>Full lists of members and affiliations appear in the **Supplementary Note**. <sup>79</sup>Finnish Institute for Molecular Medicine (FIMM), Helsinki University, Helsinki, Finland. <sup>80</sup>Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. <sup>81</sup>Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Correspondence should be addressed to D.A. ([altshuler@molbio.mgh.harvard.edu](mailto:altshuler@molbio.mgh.harvard.edu)) or K.S. ([kstefans@decode.is](mailto:kstefans@decode.is)).

## ONLINE METHODS

**Sequencing and genotyping.** Individuals were selected for initial sequencing from several population-based cohorts from Finland and Sweden. A custom hybrid selection array was used to target genes, which were sequenced on an Illumina HiSeq 2000. Additional individuals from these same cohorts, as well as from other cohorts drawn from different European populations, were genotyped for the *SLC30A8* nonsense SNV encoding p.Arg138\* using the Illumina HumanExome v1.1 array. All sequenced individuals were also genotyped, with data showing 100% concordance.

Icelandic individuals were genotyped for the frameshift variant encoding p.Lys34Serfs\*50 using a combination of whole-genome sequencing and imputation (either direct imputation based on chip genotyping or family-based imputation). Sanger sequencing was used to confirm carriers. Norwegian individuals were genotyped with a fragment length–based method using differentially labeled fluorescent primers, with Sanger sequencing again used to confirm carriers. Further *SLC30A8* sequencing (aimed at identifying additional carriers of rare variants) was performed as part of a whole-exome sequencing experiment, with the Agilent SureSelect Human All Exon platform used to capture exons and an Illumina HiSeq 2000 used for sequencing.

These studies were performed using protocols approved by the ethics committees of Helsinki University Hospital, Finland, and Lund University,

the Data Protection Commission of Iceland and the National Bioethics Committee of Iceland, the Regional Committee for Research Ethics and the Norwegian Data Inspectorate, and the Massachusetts Institute of Technology Institutional Review Board, as well as with informed consent from all participants.

**Association analysis.** Association analysis was performed separately for three groups of variants: p.Arg138\*, p.Lys34Serfs\*50 and the remaining variants. For p.Arg138\*, association analysis was separate for each analyzed cohort and used a linear mixed model to account for sample structure, including population stratification and genetic relatedness. Results were combined via a fixed-effects meta-analysis. For p.Lys34Serfs\*50, association analysis was performed in Iceland using logistic regression, with controls matched to cases on the basis of how informative the imputed genotypes were, and in Norway using a simple logistic regression with significance calculated via the score statistic. For the remaining variants, all individuals were analyzed jointly via a collapsing method, regressing phenotype on the presence of any variant, with a linear mixed model used to account for sample structure. The resulting three association statistics were combined via a random-effects meta-analysis to obtain combined estimates of effect size and statistical significance.